Home » Stocks » ENOB

Enochian Biosciences, Inc. (ENOB)

Stock Price: $3.80 USD 0.08 (2.15%)
Updated May 12, 2021 4:00 PM EDT - Market closed
Market Cap 177.12M
Revenue (ttm) n/a
Net Income (ttm) -10.94M
Shares Out 47.61M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $3.80
Previous Close $3.72
Change ($) 0.08
Change (%) 2.15%
Day's Open 3.75
Day's Range 3.72 - 4.00
Day's Volume 185,399
52-Week Range 2.60 - 13.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the release ...

3 hours ago - GlobeNewsWire

LOS ANGELES, May 12, 2021 /PRNewswire/ -- (NASDAQ: ENOB) –  A novel approach to HIV cell therapy developed by Dr. Serhat Gumrukçu (Dr. Serhat), Director of the Seraph Research Institute (SRI), and his t...

12 hours ago - PRNewsWire

Pre-market movers this morning include some high-profile top gainers and losers. Take a look at this list that includes NFT stocks and EV plays.

Other stocks mentioned: APOP, CIDM, CNET, CSCW, NGA, OGEN, SGOC ...
1 month ago - InvestorPlace

LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infec...

1 month ago - GlobeNewsWire

LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be m...

2 months ago - GlobeNewsWire

LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences , a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today annou...

8 months ago - GlobeNewsWire

Shares of Enochian Biosciences Inc (NASDAQ: ENOB) were trading more than 75% higher Monday in reaction to the company's announcement regarding a positive FDA meeting regarding its HIV candidate.

11 months ago - Benzinga

Enochian BioSciences Inc. (NASDAQ: ENOB) shares more than doubled to start out the week after the company received a critical update from the U.S.

11 months ago - 24/7 Wall Street

Company encouraged by strong alignment with views of FDA’s CBER regarding ENOB-HV-01 LOS ANGELES, June 08, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on g...

11 months ago - GlobeNewsWire

• First presentation of a novel approach to potentially cure HIV   -  An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells

11 months ago - GlobeNewsWire

LOS ANGELES, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on genetically modified cellular and immune therapy for infectious diseases and cancer, announces that the FDA ha...

1 year ago - GlobeNewsWire

LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the acquisit...

1 year ago - GlobeNewsWire

- Gregg Alton, the former interim CEO of Gilead Sciences, a company he served in many key roles during his more than 20 year tenure, and; - Carol Brosgart, MD, Clinical Professor of Medicine at the ...

1 year ago - GlobeNewsWire

LOS ANGELES, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that important scientific findings ...

1 year ago - GlobeNewsWire

Enochian Biosciences Is A House Of Cards - The Pipeline Is Entirely Pre-Clinical And Management Has A Questionable History

1 year ago - Seeking Alpha

About ENOB

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 inno... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
ENOB
Full Company Profile

Financial Performance

Financial Statements